From: Validation and clinical interpretability of PsAID - psoriatic arthritis impact of disease
Variables | n = 160 |
---|---|
Age (years) – mean ± SD | 54.0 ± 11.2 |
Gender – n (%) | |
Female | 80 (50.0) |
Male | 80 (50.0) |
Race self-declaration – n (%) | |
White | 99 (61.9) |
Black | 14 (8.8) |
Mulatto | 37 (23.1) |
Other | 10 (6.2) |
Educational level – n (%) | |
Elementary school incomplete | 52 (32.5) |
Elementary school complete | 26 (16.3) |
Secondary school | 56 (35.1) |
College | 21 (13.2) |
Postgraduate | 5 (3.1) |
Current employment status – n (%) | |
Active | 66 (41.3) |
Away due to PsA | 33 (20.6) |
Retired due to PsA | 20 (12.5) |
Retired or away for other reasons | 31 (19.4) |
Unemployed | 10 (6.3) |
Classification of BMI – n (%) | |
Eutrophic | 35 (21.9) |
Overweight | 70 (43.8) |
Obesity | 55 (34.4) |
Smoker – n (%) | 24 (15.0) |
Alcoholic – n (%) | 19 (11.9) |
Metabolic syndrome | 100 (62.5) |
Comorbidities | |
Systemic Arterial Hypertension | 82 (51.3) |
Diabetes Mellitus | 34 (21.3) |
Dyslipidemia | 106 (66.3) |
Depressive Disorder | 31 (19.4) |
Fibromyalgia | 28 (17.5) |
Duration of cutaneous disease/psoriasis (years) - median (P25-P75) | 18 (8-27) |
Time of PsA symptoms (years) - median (P25-P75) | 8 (5-14) |
Type of psoriasis – n (%) | |
Plaque | 142 (88,8) |
Palm plantar | 10(6,3) |
Others | 8(5,1) |
Onicopathy – n (%) | 54 (33,8) |
Current treatment – n (%) | |
Biological | 107 (66,9) |
Joint count with edema - median (P25-P75) | 1 (0-3) |
Counting of joints with painful - median (P25-P75) | 2 (0-5) |
Enthesitis (SPARCC ≥1) – n (%) | 33 (20.6) |
Radiographic changed – n (%) | 115 (71.9) |
PASI≤1 – n (%) | 66 (41.3) |
Type of PsA involvment – n(%) | |
Peripheral | 109 (68,1) |
Axial | 3 (1,9) |
Mixed | 48 (30,0) |